ORCID
- Michael A. Jarvis: 0000-0002-0124-4061
Abstract
AbstractThe COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.
Publication Date
2021-04-16
Publication Title
Nature Communications
Volume
12
Issue
1
ISSN
2041-1723
Embargo Period
2021-08-14
Recommended Citation
Jarvis, M., Rosenke, K., Hansen, F., Schwarz, B., Feldmann, F., Haddock, E., Rosenke, R., Barbian, K., Meade-White, K., Okumura, A., Leventhal, S., Hawman, D., Ricotta, E., Bosio, C., Martens, C., Saturday, G., & Feldmann, H. (2021) 'Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model', Nature Communications, 12(1). Available at: 10.1038/s41467-021-22580-8
- Citations
- Citation Indexes: 111
- Patent Family Citations: 1
- Policy Citations: 1
- Usage
- Downloads: 6
- Abstract Views: 2
- Captures
- Readers: 146
- Mentions
- Blog Mentions: 2
- News Mentions: 15
